Receptor, Fibroblast Growth Factor, Type 3
Research News and Information

Monday, November 23, 2009

Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development.

30 Oct 2009 Bladder cancer develops through different pathways, provisionally entitled "papillary" and "invasive." Carcinoma in situ (CIS) is thought to be the precursor of invasive bladder cancer. However, little is known about chromosomal alterations of these ... Read more...

No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.

30 Oct 2009 Mutations in the fibroblast growth factor receptor 3 (FGFR3) gene causing constitutive oncogenic protein activation have been shown to be frequent in papillary noninvasive bladder tumours and are associated with a low risk of progression and a ... Read more...

Cell adaptation to activated FGFR3 includes Sprouty4 up regulation to inhibit the receptor-mediated ERKs activation from the endoplasmic reticulum.

13 Sep 2009 The kinase activity of the thanatophoric dysplasia type II-fibroblast growth factor receptor 3 mutant (TDII-FGFR3) hampers its maturation. As a consequence, the immature receptor activates extracellular regulated kinases (ERKs) from the endoplasmic ... Read more...

Latest indexed articles for 'Receptor, Fibroblast Growth Factor, Type 3'

These are the very latest articles for this heading:

• FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma. 30 Oct 2009
• Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. 30 Oct 2009
• No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. 30 Oct 2009
• Cell adaptation to activated FGFR3 includes Sprouty4 up regulation to inhibit the receptor-mediated ERKs activation from the endoplasmic reticulum. 13 Sep 2009
• Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. 10 Aug 2009
• Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations. 30 Jul 2009
• Plasma cell myeloma. 30 Jul 2009
• Acanthosis nigricans and insulin sensitivity in patients with achondroplasia and hypochodroplasia due to FGFR3 mutations. 19 Jul 2009
• Hill coefficient analysis of transmembrane helix dimerization. 13 Jul 2009
• FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14). 4 Jul 2009
• Comparison of expression profiles of several fibroblast growth factor receptors in the mouse jejunum: suggestive evidence for a differential radioprotective effect among major FGF family members and the potency of FGF1. 29 Jun 2009
• The absence of BRAF, FGFR3, and PIK3CA mutations differentiates lentigo simplex from melanocytic nevus and solar lentigo. 16 Jun 2009
• FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. 8 Jun 2009
• Significant phenotypic variability of Muenke syndrome in identical twins. 30 May 2009
• Thanatophoric dysplasia caused by double missense FGFR3 mutations. 30 May 2009
• Stiff skin syndrome: evidence for an inflammation-independent fibrosis? 23 May 2009
• Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. 17 May 2009
• A young patient with polyarthralgia and hearing loss: a case report of Muenke syndrome. 14 May 2009
• Methylation status of CpG islands in the promoter regions of signature genes during chondrogenesis of human synovium-derived mesenchymal stem cells. 29 Apr 2009
• The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. 29 Apr 2009

See a longer list of these articles.

Technical information about 'Receptor, Fibroblast Growth Factor, Type 3'

Definition: A fibroblast growth factor receptor that regulates CHONDROCYTE growth and CELL DIFFERENTIATION. Mutations in the gene for fibroblast growth factor receptor 3 have been associated with ACHONDROPLASIA; THANATOPHORIC DYSPLASIA and NEOPLASTIC CELL TRANSFORMATION.

Registry Number: EC 2.7.1.112

Descriptor UI: D051498

Alternative terms: Receptor, Fibroblast Growth Factor, Type 3; Fibroblast Growth Factor Receptors 3; Fibroblast Growth Factor Receptor 3; FGFR3 Protein; Receptor 3, Fibroblast Growth Factor;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D08.811.913.696.620.682.725.400.179; D12.776.543.750.060.442; D12.776.543.750.750.400.370.875; D12.776.624.664.700.792;

History Note: 2006(1992)